Interferon induction, evasion, and paradoxical roles during SARS‐CoV‐2 infection*
Authors:
Open Access
- 1 July 2022
- journal article
- review article
- Published by Wiley in Immunological Reviews
- Vol. 309 (1) , 12-24
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the causative agent of coronavirus disease 2019 (COVID‐19), has caused millions of deaths in the past two years. Although initially little was understood about this virus, recent research has significantly advanced and landed interferons (IFNs) in the spotlight. While Type I and III IFN have long been known as central to antiviral immunity, in the case of COVID‐19 their role was initially controversial. However, the protective function of IFN is now well supported by the identification of human deficiencies in IFN responses as a predictor of disease severity. Here, we will review the cell types and pathways that lead to IFN production as well as the importance of IFN timing and location for disease outcome. We will further discuss the mechanisms that SARS‐CoV‐2 uses to evade IFN responses, and the current efforts to implement IFNs as therapeutics in the treatment of COVID‐19. It is essential to understand the relationships between SARS‐CoV‐2 and IFN to better inform treatments that exploit IFN functions to alleviate COVID‐19.Keywords
Funding Information
- NIH Office of the Director (AI145314, AI113923, AI132122)
This publication has 141 references indexed in Scilit:
- Signal Recognition Particle: An Essential Protein-Targeting MachineAnnual Review of Biochemistry, 2013
- Both G3BP1 and G3BP2 contribute to stress granule formationGenes to Cells, 2012
- Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivoJournal of Experimental Medicine, 2011
- Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunityJournal of Experimental Medicine, 2011
- Interferon-Stimulated Gene 15 and the Protein ISGylation SystemJournal of Interferon & Cytokine Research, 2011
- Induction of a Striking Systemic Cytokine Cascade prior to Peak Viremia in Acute Human Immunodeficiency Virus Type 1 Infection, in Contrast to More Modest and Delayed Responses in Acute Hepatitis B and C Virus InfectionsJournal of Virology, 2009
- Persistent Virus Infection Inhibits Type I Interferon Production by Plasmacytoid Dendritic Cells to Facilitate Opportunistic InfectionsCell Host & Microbe, 2008
- Tetherin inhibits retrovirus release and is antagonized by HIV-1 VpuNature, 2008
- Control of coronavirus infection through plasmacytoid dendritic-cell–derived type I interferonBlood, 2006
- Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial AntigensJournal of Experimental Medicine, 2001